Epizyme Inc. | Balance Sheet

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
123,564.00
190,095.00
208,323.00
242,192.00
276,439.00
240,304
Total Accounts Receivable
33,667.00
2,075.00
262.00
318.00
631.00
20,746
Other Current Assets
2,421.00
2,840.00
4,478.00
6,162.00
8,734.00
11,485
Total Current Assets
159,652.00
195,010.00
213,063.00
248,672.00
285,804.00
272,535
Net Property, Plant & Equipment
2,157.00
3,620.00
4,089.00
3,124.00
2,527.00
2,057
Other Assets
1,179.00
573.00
751.00
645.00
1,028.00
447
Total Assets
162,988.00
199,203.00
217,903.00
252,441.00
289,359.00
275,501
ST Debt & Current Portion LT Debt
-
-
561.00
620.00
110.00
Accounts Payable
4,698.00
8,300.00
4,653.00
4,994.00
7,001.00
Other Current Liabilities
29,875.00
8,745.00
13,235.00
16,007.00
17,553.00
Total Current Liabilities
34,573.00
17,045.00
18,449.00
21,621.00
24,664.00
Long-Term Debt
-
-
730.00
110.00
-
Other Liabilities
24,102.00
21,876.00
29,192.00
29,010.00
29,324.00
Total Liabilities
58,675.00
38,921.00
48,371.00
50,741.00
53,988.00
Common Equity (Total)
104,313.00
160,282.00
169,532.00
201,700.00
235,371.00
Total Shareholders' Equity
104,313.00
160,282.00
169,532.00
201,700.00
235,371.00
Total Equity
104,313.00
160,282.00
169,532.00
201,700.00
235,371.00
Liabilities & Shareholders' Equity
162,988.00
199,203.00
217,903.00
252,441.00
289,359.00

About Epizyme

View Profile
Address
400 Technology Square
Cambridge Massachusetts 02139
United States
Employees -
Website http://www.epizyme.com
Updated 07/08/2019
Develops therapeutics for the treatment of patients with genetically defined cancers .